Haleon PLC

Board/Management Information • Feb 25, 2025

National Storage Mechanism | Additional information

RNS Number : 4085Y

Haleon PLC

25 February 2025

Haleon plc: Board Change

25 February 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the following change to the Board.

Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 10%, and in line with the Pfizer Relationship Agreement with Haleon plc, Bryan Supran, Non-Executive Director and representative of Pfizer Inc., stepped down from the Board on 25 February 2025.

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Bryan for his contributions to the Board's discussions and for being part of the Haleon journey from the initial joint-venture in 2019 through demerger to today. We wish him all the very best for the future. "

The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R.

Amanda Mellor  

Company Secretary  

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit   www.haleon.com . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAPKPBBBBKDDBB